2012

San Francisco, CA., December 3, 2012 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics, today announced that it is scheduled to present at LD MICRO’s 5th Annual Conference on Thursday, December 6, 2013, at 10 a.m. Pacific Standard Time. The December 5-6 conference is to be held at the Luxe Sunset […]

San Francisco, Calif., November 14, 2012 – CollabRx, Inc. (NASDAQ: CLRX) today announced financial results for the Second Quarter Fiscal Year 2013, which ended September 30, 2012. Fiscal 2013 Second Quarter Financial Statement Highlights The Company’s Net Loss per share in the Second Quarter of Fiscal Year 2013 was ($0.68), compared with ($0.28) in the […]

San Francisco, Calif., November 13, 2012 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics, today announced that it is scheduled to present at the National Investment Banking Association (NIBA) Conference November 14-16, 2012, at The Venetian Resort Hotel-Casino in Las Vegas. CollabRx Chairman and Co-CEO Thomas R. Mika will be presenting […]

San Francisco, Calif., October 9, 2012 – CollabRx, Inc. (NASDAQ: CLRX) today announces that Dr. Gavin Gordon, CollabRx Head of Business Development & Alliances, will participate as an invited speaker in the annual conference of the Oregon Bioscience Association to be held on October 9th and 10th at Marylhurst University. The conference, titled “Bioscience Digitization […]

Life Technologies’ Cancer Panels to be paired with CollabRx’s Interpretive Analytics San Francisco, Calif., October 3, 2012 – CollabRx, Inc. (NASDAQ: CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies’ global cancer diagnostics development and its […]

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. Proteins provide clues to outcomes An international group of researchers report promising results with a test that may identify patients likely to […]

Results of the largest global gene study of breast cancer tissue ever performed appeared recently in Nature. These results could “…. pave the way for doctors in the future to diagnose the type of breast cancer a woman has, the types of drugs that will work, and those that won’t, in a much more precise […]

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalised approach to cancer treatments. The study is published in Nature on Thursday 29 March 2012. The team uncovered hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. One of the […]

In a report that appears in the journal Nature as an advanced online publication, researchers describe one of the first studies to demonstrate the value of “co-clinical” trials, in which drugs targeting cancers with specific genetic mutations are tested simultaneously in patients and in lab animals with the same type of tumor. The arrangement enables investigators to […]